ReviewThyroid research2026
TSH receptor autoantibodies - a personal experience.
Review in Thyroid research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nineteen fifty six was a pivotal year in our understanding of thyroid disease with the discovery of long acting thyroid stimulator (LATS) in the serum of patients with Graves' disease and autoantibodies to thyroglobulin in Hashimoto's disease. Soon after its discovery, LATS was shown to be a thyroid stimulating autoantibody and then in 1974 to be an autoantibody to the TSH receptor. Further major advances were made in 1989 (cloning the TSH receptor) and production of the thyroid stimulating human monoclonal autoantibody M22™ in 2002. The availability of M22™ enabled determination of the crystal structure of the TSH receptor in complex with M22™. Subsequently, three more human monoclonal autoantibodies to the TSH receptor were produced. One with stimulating activity (K1-18™) and two with blocking (antagonist) activity (5C9™ and K1-70™). Cryo-EM analysis of these four monoclonal autoantibodies in complex with the TSH receptor has provided a detailed understanding of how TSH receptor autoantibodies with different properties function. The monoclonal autoantibody K1-70™ with powerful TSH receptor blocking activity is in clinical trials and shows the expected beneficial effect on Graves' hyperthyroidism and Graves' ophthalmopathy. It is an exciting new TSH receptor specific drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.